Compare SMSI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMSI | LGVN |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 34.0M |
| IPO Year | 2017 | 2021 |
| Metric | SMSI | LGVN |
|---|---|---|
| Price | $0.69 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 135.4K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.94 | 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,363,000.00 | $709,000.00 |
| Revenue This Year | $13.97 | N/A |
| Revenue Next Year | $53.35 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.48 |
| 52 Week High | $1.30 | $1.83 |
| Indicator | SMSI | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 60.31 |
| Support Level | $0.67 | $0.69 |
| Resistance Level | $0.84 | $1.22 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 9.60 | 68.92 |
Smith Micro Software Inc provides software solutions that simplify and enhance the mobile experience to some of the wireless service providers around the globe. The company's solutions include SafePath product suite provides comprehensive and easy-to-use tools to protect family digital lifestyles and manage connected devices both inside and outside the home; CommSuite premium messaging platform helps mobile service providers deliver a next-generation voicemail experience to mobile subscribers, while monetizing a legacy cost-center; and ViewSpot its retail display management platform provided wireless carriers and retailers with a way to bring powerful on-screen, interactive demos to life. It operates in single segment: Wireless.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.